deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05736731

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (EVEREST-1)

A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530, an Autologous Logic-gated Tmod™ Chimeric Antigen Receptor T Cell (CAR T), in Heterozygous HLA-A*02 Adult Subjects With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Sponsor: A2 Biotherapeutics Inc.

Conditions CRC Cancer Colorectal Adenocarcinoma Colorectal Cancer Colorectal Cancer Metastatic Colorectal Neoplasms NSCLC NSCLC, Recurrent Non Small Cell Lung Cancer Non Small Cell Lung Cancer Recurrent Non-Small Cell Squamous Lung Cancer Pancreas Cancer Pancreatic Cancer Pancreatic Neoplasms Solid Tumor Solid Tumor, Adult
Interventions A2B530 xT-Onco with HLA-LOH Assay
Updated 20 times since 2023 Last updated: Apr 23, 2025 Started: Apr 28, 2023 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05736731, this PHASE1/PHASE2 trial focuses on CRC and Cancer and remains ongoing. Sponsored by A2 Biotherapeutics Inc., it has been updated 20 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Apr 2025 · 4 months · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Apr 2025 — May 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Dec 2024 — Apr 2025 [monthly]

    Recruiting PHASE1/PHASE2

  5. Nov 2024 — Dec 2024 [monthly]

    Recruiting PHASE1/PHASE2

▶ Show 15 earlier versions

  1. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE1/PHASE2

  2. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

  3. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. Apr 2024 — May 2024 [monthly]

    Recruiting PHASE1_PHASE2

  6. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE1_PHASE2

  7. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE1_PHASE2

  8. Dec 2023 — Feb 2024 [monthly]

    Recruiting PHASE1_PHASE2

  9. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE1_PHASE2

  10. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE1_PHASE2

  11. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE1_PHASE2

  12. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jun 2023 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  14. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  15. Mar 2023 — May 2023 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • A2 Biotherapeutics Inc.
  • Tempus AI
Data source: A2 Biotherapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations